Kevin Kun-Chin Liu;Asako Nagata;John Charles Kath;Simon Paul Planken;Theodore Otto Johnson, JR.;Hengmiao Cheng;Scott Channing Sutton;Sajiv Krishnan Nair;Elizabeth Ann Lunney
发明人:
Hengmiao Cheng,Theodore Otto Johnson, JR.,John Charles Kath,Kevin Kun-Chin Liu,Elizabeth Ann Lunney,Asako Nagata,Sajiv Krishnan Nair,Simon Paul Planken,Scott Channing Sutton,Cheng, Hengmiao,Johnson Jr., Theodore Otto,Kath, John Charles,Liu, Kevin Kun-chin,Lunney, Elizabeth Ann,Nagata, Asako,Nair, Sajiv Krishnan,Planken, Simon Paul,Sutton, Scott Channing
申请号:
US13617035
公开号:
US20130079324A1
申请日:
2012.09.14
申请国别(地区):
US
年份:
2013
代理人:
摘要:
The present invention relates to compounds of formula (I)or pharmaceutically acceptable salts thereof, wherein Q, T, V, W, X, Y, Z, ring A, R1, R2, R3, R4, R5, R5a, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17 and m are defined herein. There novel pyrrolopyrimidine and purine derivatives are useful in the treatment of abnormal cell growth, such as cancer, in mammals. Additional embodiments relate to pharmaceutical compositions containing the compounds and to methods of using the compounds and compositions in the treatment of abnormal cell growth in mammals.